Pioneering Clinical Technologies (PCT) is a pharmaceutical research & development company that aims to bring to market a novel treatment option for patients with Peripheral Artery Disease (PAD). This novel treatment, Cenderitide (CD-NP), is a synthetic natriuretic peptide, administered using a custom designed subcutaneous infusion pump. Cenderitide is expected to significantly increase walking duration and the quality of life of patients with PAD.